FDA Approves Higher Dose of Ozempic Diabetes Drug

FDA has approved a higher 2 mg dose of Novo Nordisk’s Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 analog indicated along with diet and exercise to improve blood sugar in adults with Type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with Type 2 diabetes and known heart disease. With this approval, the company says, Ozempic will be available in three dosage levels.

Read more